{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T10:45:29Z","timestamp":1774003529128,"version":"3.50.1"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020796","name":"SMA Europe","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020796","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007721","name":"Cure SMA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007721","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials Communications"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.conctc.2026.101601","type":"journal-article","created":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T05:57:43Z","timestamp":1768715863000},"page":"101601","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["An updated review of the SMA clinical trial landscape in the United States: Findings from analysis of recruitment targets on ClinicalTrials.gov and a survey of SMA clinical trial sites on factors affecting site capacity and readiness"],"prefix":"10.1016","volume":"49","author":[{"given":"Fatou","family":"Sarr","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilse","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline","family":"Glascock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0747-4669","authenticated-orcid":false,"given":"Mary","family":"Curry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.conctc.2026.101601_bib1","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1007\/s00431-023-04883-8","article-title":"New therapies for spinal muscular atrophy: where we stand and what is next","volume":"182","author":"Antonaci","year":"2023","journal-title":"Eur. J. Pediatr."},{"issue":"6","key":"10.1016\/j.conctc.2026.101601_bib2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s11940-019-0568-z","article-title":"Current treatment options in Neurology\u2014SMA therapeutics","volume":"21","author":"Waldrop","year":"2019","journal-title":"Curr. Treat. Options Neurol."},{"issue":"15","key":"10.1016\/j.conctc.2026.101601_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241511939","article-title":"Spinal muscular atrophy: the past, present, and future of diagnosis and treatment","volume":"24","author":"Nishio","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"19","key":"10.1016\/j.conctc.2026.101601_bib4","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241914873","article-title":"Spinal muscular atrophy: an evolving scenario through new perspectives in diagnosis and advances in therapies","volume":"24","author":"Angilletta","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.conctc.2026.101601_bib6","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/s41591-022-01866-4","article-title":"Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the phase III SPR1NT trial","volume":"28","author":"Strauss","year":"2022","journal-title":"Nat. Med."},{"issue":"7","key":"10.1016\/j.conctc.2026.101601_bib7","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/s41591-022-01867-3","article-title":"Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the phase III SPR1NT trial","volume":"28","author":"Strauss","year":"2022","journal-title":"Nat. Med."},{"issue":"9","key":"10.1016\/j.conctc.2026.101601_bib8","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/gt.2017.52","article-title":"The clinical landscape for SMA in a new therapeutic era","volume":"24","author":"Talbot","year":"2017","journal-title":"Gene Ther."},{"issue":"1","key":"10.1016\/j.conctc.2026.101601_bib9","doi-asserted-by":"crossref","first-page":"16","DOI":"10.17712\/nsj.2019.1.20180321","article-title":"Effect of new modalities of treatment on physicians management plan for patients with spinal muscular atrophy","volume":"24","author":"Bashiri","year":"2019","journal-title":"Neurosciences (Riyadh)"},{"issue":"1","key":"10.1016\/j.conctc.2026.101601_bib10","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.conctc.2026.101601_bib11","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/mus.24497","article-title":"Spinal muscular atrophy: diagnosis and management in a new therapeutic era","volume":"51","author":"Arnold","year":"2015","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.conctc.2026.101601_bib12","series-title":"Biogen, Spinraza","year":"2016"},{"key":"10.1016\/j.conctc.2026.101601_bib13","author":"Cure"},{"issue":"1","key":"10.1016\/j.conctc.2026.101601_bib14","first-page":"118","article-title":"The SMA clinical trial readiness program: creation and evaluation of a program to enhance SMA trial readiness in the United States, orphanet J","volume":"15","author":"Peterson","year":"2020","journal-title":"Rare Dis."},{"key":"10.1016\/j.conctc.2026.101601_bib15","author":"Cure"},{"key":"10.1016\/j.conctc.2026.101601_bib16","year":"2020"},{"key":"10.1016\/j.conctc.2026.101601_bib17","series-title":"Zolgensma","year":"2019"},{"issue":"7","key":"10.1016\/j.conctc.2026.101601_bib18","article-title":"Spinal muscular atrophy: from approved therapies to future therapeutic targets for personalized medicine","volume":"2","author":"Chaytow","year":"2021","journal-title":"Cell Rep. Med."},{"issue":"9","key":"10.1016\/j.conctc.2026.101601_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21093297","article-title":"New and developing therapies in spinal muscular atrophy: from genotype to phenotype to treatment and where do we stand?","volume":"21","author":"Chen","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.conctc.2026.101601_bib20","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1177\/17407745231177885","article-title":"Now is the time to fix the clinical research workforce crisis, clin","volume":"20","author":"Freel","year":"2023","journal-title":"Trials"},{"issue":"1","key":"10.1016\/j.conctc.2026.101601_bib21","first-page":"240","article-title":"What role can decentralized trial designs play to improve rare disease studies?, orphanet J","volume":"17","author":"Moore","year":"2022","journal-title":"Rare Dis."},{"issue":"1","key":"10.1016\/j.conctc.2026.101601_bib22","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s13063-020-4079-8","article-title":"Streamlining and cycle time reduction of the startup phase of clinical trials","volume":"21","author":"Abu-Shaheen","year":"2020","journal-title":"Trials"},{"issue":"1","key":"10.1016\/j.conctc.2026.101601_bib23","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1186\/s13063-018-2645-0","article-title":"A checklist for clinical trials in rare disease: obstacles and anticipatory actions-lessons learned from the FOR-DMD trial","volume":"19","author":"Crow","year":"2018","journal-title":"Trials"},{"key":"10.1016\/j.conctc.2026.101601_bib24","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ygyno.2024.01.008","article-title":"How far is too far? Cancer prevention and clinical trial enrollment in geographically underserved patient populations","volume":"184","author":"Ring","year":"2024","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.conctc.2026.101601_bib25","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s13063-023-07177-4","article-title":"Site-specific factors associated with clinical trial recruitment efficiency in general practice settings: a comparative descriptive analysis","volume":"24","author":"Tew","year":"2023","journal-title":"Trials"},{"key":"10.1016\/j.conctc.2026.101601_bib26","year":"2023"},{"issue":"5","key":"10.1016\/j.conctc.2026.101601_bib27","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1177\/17407745211015924","article-title":"Clinical trials site recruitment optimisation: guidance from clinical trials: impact and quality","volume":"18","author":"Zahren","year":"2021","journal-title":"Clin. Trials"},{"key":"10.1016\/j.conctc.2026.101601_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2019.105918","article-title":"Improving the quality conduct and efficiency of clinical trials with training: recommendations for preparedness and qualification of investigators and delegates","volume":"89","author":"Bechtel","year":"2020","journal-title":"Contemp. Clin. Trials"},{"issue":"1","key":"10.1016\/j.conctc.2026.101601_bib29","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1200\/OP.20.00821","article-title":"Recommendations to streamline and standardize clinical trial site feasibility assessments: an ASCO research statement","volume":"17","author":"Kurbegov","year":"2021","journal-title":"JCO Oncol. Pract."},{"issue":"1","key":"10.1016\/j.conctc.2026.101601_bib30","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41746-022-00603-y","article-title":"Opportunities and counterintuitive challenges for decentralized clinical trials to broaden participant inclusion","volume":"5","author":"Goodson","year":"2022","journal-title":"npj Digit. Med."},{"key":"10.1016\/j.conctc.2026.101601_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1309073","article-title":"Reimagining the joint task force core competency framework for rural and frontier clinical research professionals conducting hybrid and decentralized trials","volume":"14","author":"Besel","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"3","key":"10.1016\/j.conctc.2026.101601_bib32","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1177\/13524585221100401","article-title":"Decentralised clinical trials in multiple sclerosis research, mult","volume":"29","author":"Garjani","year":"2023","journal-title":"Scler"},{"key":"10.1016\/j.conctc.2026.101601_bib33","doi-asserted-by":"crossref","first-page":"35","DOI":"10.21693\/1933-088X-21.2.35","article-title":"What rare disease patient advocacy groups are doing to mitigate the effects of disparities","volume":"21","author":"Drell","year":"2022","journal-title":"Advances in Pulmonary Hypertension"},{"key":"10.1016\/j.conctc.2026.101601_bib34","article-title":"Cure SMA community update survey: patient and caregiver reported rationale for combination and sequential therapy","volume":"vol.2024","author":"Belter","year":"2023"},{"issue":"1","key":"10.1016\/j.conctc.2026.101601_bib35","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1186\/s12887-022-03671-x","article-title":"Advances and limitations for the treatment of spinal muscular atrophy","volume":"22","author":"Day","year":"2022","journal-title":"BMC Pediatr."},{"issue":"5","key":"10.1016\/j.conctc.2026.101601_bib36","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.nmd.2021.01.012","article-title":"Understanding European patient expectations towards current therapeutic development in spinal muscular atrophy","volume":"31","author":"Gusset","year":"2021","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.conctc.2026.101601_bib37","doi-asserted-by":"crossref","first-page":"809","DOI":"10.3233\/JND-221538","article-title":"Clinical trial readiness for spinal muscular atrophy: experience of an international educational-training initiative","volume":"9","author":"Tizzano","year":"2022","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.conctc.2026.101601_bib38","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jpeds.2021.04.062","article-title":"Capacity building in a new clinical trials network through inter-network collaboration","volume":"240","author":"Knight","year":"2022","journal-title":"J. Pediatr."},{"issue":"18","key":"10.1016\/j.conctc.2026.101601_bib39","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.21037\/atm-21-5496","article-title":"Novel clinical trial design and analytic methods to tackle challenges in therapeutic development in rare diseases","volume":"10","author":"Li","year":"2022","journal-title":"Ann. Transl. Med."},{"issue":"3\u20134","key":"10.1016\/j.conctc.2026.101601_bib40","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1177\/09727531211046365","article-title":"Spinal muscular atrophy therapeutics in India: parental hopes and despair","volume":"28","author":"Suthar","year":"2021","journal-title":"Ann. Neurosci."},{"issue":"8","key":"10.1016\/j.conctc.2026.101601_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgph.0000890","article-title":"Rare disease patients in India are rarely involved in international orphan drug trials","volume":"2","author":"Chakraborty","year":"2022","journal-title":"PLOS Global Public Health"},{"issue":"1","key":"10.1016\/j.conctc.2026.101601_bib42","first-page":"44","article-title":"SMA-EUROPE workshop report: opportunities and challenges in developing clinical trials for spinal muscular atrophy in Europe, orphanet J","volume":"8","author":"Kayadjanian","year":"2013","journal-title":"Rare Dis."},{"issue":"2","key":"10.1016\/j.conctc.2026.101601_bib43","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24021130","article-title":"Gene therapy in ALS and SMA: advances, challenges and perspectives","volume":"24","author":"Lejman","year":"2023","journal-title":"Int. J. Mol. Sci."}],"container-title":["Contemporary Clinical Trials Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451865426000086?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451865426000086?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T08:26:40Z","timestamp":1773995200000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2451865426000086"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":42,"alternative-id":["S2451865426000086"],"URL":"https:\/\/doi.org\/10.1016\/j.conctc.2026.101601","relation":{},"ISSN":["2451-8654"],"issn-type":[{"value":"2451-8654","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An updated review of the SMA clinical trial landscape in the United States: Findings from analysis of recruitment targets on ClinicalTrials.gov and a survey of SMA clinical trial sites on factors affecting site capacity and readiness","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.conctc.2026.101601","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101601"}}